| May 9, 2024 |
Aardvark Therapeutics Announces $85 Million Oversubscribed Series C Financing |
 |
| April 25, 2024 |
Regeneron Signs Mammoth Gene Editing Deal Worth $100M Upfront |
 |
| April 22, 2024 |
Bristol Myers Signs $380 Million CAR-T Therapies Supply Deal with Cellares |
 |
| April 10, 2024 |
Vertex Pharmaceuticals to buy Alpine Immune Sciences for $4.9 billion |
 |
| March 25, 2024 |
Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction |
 |
| March 18, 2024 |
KeChow Pharma Announces NMPA Approval of Tunlametinib (HL-085) as the First Targeted Therapy for Patients with NRAS Mutated Advanced Melanoma and Previously Treated with PD-1/PD-L1 |
 |
| March 5, 2024 |
Nalu Medical Closes $85 Million Series E Round |
 |
| February 15, 2024 |
Firefly Bio Debuts With $94 Million Series A Financing |
 |
| January 25, 2024 |
Biotech CG Oncology Soars 96% in Debut After Expanded IPO |
 |
| January 3, 2024 |
Nalu Medical Raises $65 Million Equity Financing to Advance Treatment for Chronic Neuropathic Pain |
|
| December 20, 2023 |
IMPACT Entered into Commercial Partnership with Huadong Medicine |
 |
| December 18, 2023 |
AnHeart Therapeutics and Innovent Announce China's NMPA has Granted Taletrectinib (ROS1 Inhibitor) Priority Review Designation |
|
| December 5, 2023 |
CG Oncology Receives Both FDA Fast Track and Breakthrough Therapy Designation for Cretostimogene Grenadenorepvec in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer |
|
| November 30, 2023 |
ShapeTX Expands Strategic Collaboration with Roche with Addition of a New Target |
 |
| November 30, 2023 |
Cretostimogene Grenadenorepvec Monotherapy First Results Show 75.7% Complete Response Rate at Any Time in Patients With High-Risk BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer |
|
| November 29, 2023 |
Nalu Medical Announces Positive Results of US Spinal Cord Stimulation Clinical Study in Pain Physician Journals |
|
| November 29, 2023 |
YolTech Therapeutics Raises $15 Million in Series A+ Financing to Advance Breakthrough In Vivo Gene Editing Drug Development |
 |
| November 26, 2023 |
Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta’s CD19-CAR T Cell Therapy on Cellares’ Cell Shuttle Platform |
|
| November 24, 2023 |
Everest Medicines Announces China NMPA’s Approval of Nefecon® for the Treatment of Primary IgA Nephropathy in Adult Patients |
 |
| November 21, 2023 |
LevitasBio launches LeviCell EOS system for Higher Throughput Cell Isolation and Enrichment through Levitation Technology |
 |
| November 15, 2023 |
Alpine Immune Sciences Presents New Translational Data on Povetacicept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023 |
|
| November 6, 2023 |
Alpine Immune Sciences Announces Pricing of $150 Million Public Offering |
|
| November 2, 2023 |
Alpine Immune Sciences Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late-Breaking Poster Session at the American Society of Nephrology Kidney Week 2023 |
|
| October 30, 2023 |
AnHeart Therapeutics Announces Exclusive License Agreement with Nippon Kayaku for Taletrectinib in Japan |
|
| October 24, 2023 |
Upstream Bio Announces Positive Phase 1b Interim Data in Asthma and Company Progress Toward Phase 2 |
 |
| October 19, 2023 |
Endeavor BioMedicines Enters License Agreement with Hummingbird Bioscience for Worldwide Rights to HMBD-501, a Next Generation HER3-Targeted Antibody-Drug Conjugate (ADC) |
 |
| October 10, 2023 |
ImmPACT Bio Granted FDA Fast Track Designation for IMPT-514 for the Treatment of Both Active, Refractory Lupus Nephritis and Systemic Lupus Erythematosus |
 |
| September 27, 2023 |
Everest Medicines Announces Approval of XERAVA® in Taiwan for the Treatment of Complicated Intra-Abdominal Infections in Adult Patients |
|
| September 26, 2023 |
Adela Secures $48 Million In Financing |
 |
| September 21, 2023 |
Lynk Pharmaceuticals Completes Series C2 Financing Round, with Total C Round Funding of 322 Million RMB |
 |
| September 11, 2023 |
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell’s CAR T-Cell Therapy on Cellares’ Cell Shuttle Platform |
|
| September 7, 2023 |
SinoMed to Buy Controlling Stake in eLum |
 |
| September 7, 2023 |
Otsuka Collaborates with ShapeTX to Develop Novel AAV Gene Therapies for Ocular Diseases |
|
| August 30, 2023 |
Watchmaker Genomics Announces Co-Exclusive License to Disruptive DNA Methylation Technology and Strategic Supply Agreements with Exact Sciences |
 |
| August 28, 2023 |
Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform |
|
| August 23, 2023 |
Cellares Raises $255M Series C to Launch First Integrated Development and Manufacturing Organization (IDMO) and Pioneering Smart Factory to Meet Global Demand for Life-Saving Cell Therapies |
|
| August 15, 2023 |
ImmPACT Bio Announces FDA Clearance of IND Application for Bispecific CD19/CD20 CAR T Therapy IMPT-514 for the Treatment of Refractory Systemic Lupus Erythematosus |
|
| August 2, 2023 |
CG Oncology Announces $105 Million Oversubscribed Crossover Financing to Support Continued Advancement of Clinical-Stage Bladder Cancer Pipeline |
|
| June 15, 2023 |
Zentalis Prices $250 Million Stock Offering |
 |
| June 8, 2023 |
Upstream Bio Announces $200M Series B Financing to Advance UPB-101 for Allergic and Inflammatory Diseases |
|
| June 1, 2023 |
Impact Therapeutics Entered into Global Partnership with Eikon Therapeutics to Develop and Commercialize PARP1 Selective Inhibitors |
|
| May 15, 2023 |
Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation |
 |
| April 16, 2023 |
Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences |
 |
| January 9, 2023 |
Ipsen to Acquire Albireo Accelerating Growth in Rare disease with Treatments for Several Pediatric Liver Diseases |
 |